Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test ...

Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average ...

Abbott is kickstarting the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based (CRC) screening test for ...

The SimpleScreen CRC test expands Abbott's diagnostic range, which includes Cologuard Plus.

The SimpleScreen CRC blood test, developed by Freenome, will be sold exclusively by Abbott alongside its Cologuard Plus home ...

Abbott launches SimpleScreen CRC, a blood-based colorectal cancer test for adults 45+, showing 81.1% sensitivity and 90.4% ...

An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and ...

A new stake has been created from the San Lorenzo Honduras District. The Gulf of Fonseca Honduras Stake, which consists of the Guapinol, Marcovia, Monjaras, San Lorenzo 1st and San Lorenzo 2nd wards ...

Looking ahead to 2030, our model projects ABT could trade at an average price of $149.04, with a potential range between $111.78 and $186.30. This represents a potential 50.4% return from today’s ...

Member of Congress for the incredible people of the 24th District of Texas Previous elected office(s) sought or held: Prior to being elected as the Member of Congress for the 24th District in November ...